What is CelerisTx?
Founded in 2020, CelerisTx operates at the vanguard of biotechnology, specializing in the AI-driven development of novel degrader molecules. The company's core asset, the Celeris One platform, functions as a closed-loop discovery engine that integrates predictive biomolecular interaction modeling with biochemical validation. By streamlining the research and development lifecycle, CelerisTx addresses critical bottlenecks in medicinal chemistry. The firm maintains a dual-focus business model, actively partnering with established pharmaceutical and biotech entities while simultaneously advancing an internal drug pipeline targeting complex conditions such as neurodegenerative diseases and oncology. This integrated approach allows CelerisTx to maximize the utility of its computational engine across diverse therapeutic areas.
How much funding has CelerisTx raised?
CelerisTx has raised a total of $26.4M across 2 funding rounds:
Angel/Seed
$4.4M
Series A
$22M
Angel/Seed (2022): $4.4M with participation from i&i Biotech Fund, R42 Group, Pace Ventures Enigma, Apex Ventures, and Longevitytech.Fund
Series A (2022): $22M led by EIC Accelerator
Key Investors in CelerisTx
R42 Group
R42 Group is a venture capital fund and institute that focuses on inventing, investing, and informing in areas such as AI, deep science, biotech, and fintech.
Longevitytech.Fund
LogevityTech.fund is focused on global investments in technologies that aim to extend healthy lifespans and improve health outcomes.
EIC Accelerator
BLDG Dotacje sp. z o.o. specializes in economic consulting and securing EU grants, supporting enterprises in R&D projects and innovation capabilities.
What's next for CelerisTx?
With the recent influx of capital, CelerisTx is poised to transition from a development-focused entity to a scaling enterprise. The strategic roadmap likely involves expanding the capabilities of the Celeris One platform to handle more complex chemical entities and increasing the throughput of its validation processes. As the company continues to refine its predictive models, the focus will shift toward clinical readiness and the expansion of its partnership ecosystem. By maintaining its commitment to AI-driven innovation, CelerisTx is well-positioned to disrupt traditional drug discovery timelines, potentially reducing the time and cost associated with bringing potent degraders to market. Future milestones will likely center on the progression of its internal pipeline candidates into preclinical trials, further validating the efficacy of its computational methodology.
See full CelerisTx company page
